Basilico C, Modica C, Maione F, Vigna E, Comoglio PM. Targeting the MET Oncogene by Concomitant Inhibition of Receptor and Ligand via an Antibody-“Decoy” Strategy. Int. J. Cancer. 2018 October 1; 143:1774-1785

International Journal of Cancer - United States
doi 10.1002/ijc.32197
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Wiley

Related search

Aldehyde Dehydrogenase (ALDH); C-Met Proto-Oncogene (MET; HGFR); Epidermal Growth Factor Receptor 1 (EGFR1; HER1; ErbB1)

Science-Business eXchange
2014English

Prostaglandin F2 -F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma

Cancer Research
Cancer ResearchOncology
2009English

Targeting C-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors

PLoS ONE
Multidisciplinary
2014English

Targeting the HGF/c-Met Axis: State of Play

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

ABBV-399, a C-Met Antibody–Drug Conjugate That Targets Both MET –Amplified and C-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

Clinical Cancer Research
Cancer ResearchOncology
2016English

C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2014English

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

Receptor Trafficking Controls Weak Signal Delivery: A Strategy Used by C-Met for STAT3 Nuclear Accumulation

Journal of Cell Biology
MedicineCell Biology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy